| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| host | mouse |
| isotype | IgG1 |
| clonality | monoclonal |
| concentration | 1 mg/mL |
| applications | ELISA, ICC/IF, WB |
| available sizes | 1 mg, 100 µg, 25 µg |
mouse anti-GAPDH monoclonal antibody (GA1R) 1937
$100.00 – $2,600.00
Antibody summary
- Mouse monoclonal to GAPDH
- Suitable for: WB,ICC/IF,ELISA
- Reacts with: human, mouse, rat
- Isotype: IgG1
- 100 µg, 25 µg, 1 mg
mouse anti-GAPDH monoclonal antibody (GA1R) 1937
| antibody |
|---|
| Database link: human P04406 mouse P16858 rat P04797 |
| Tested applications WB,ICC/IF,ELISA |
| Recommended dilutions WB: 1:1000-100000 |
| Immunogen Recombinant GAPDH protein (human). |
| Size and concentration 25, 100, 1000µg and 1 mg/mL |
| Form liquid |
| Storage buffer PBS, pH 7.2, 0.05% NaN3 |
| Purity affinity purified |
| Clonality monoclonal |
| Isotype IgG1 |
| Compatible secondaries goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody 5486 goat anti-mouse IgG, H&L chain specific, biotin conjugated, Conjugate polyclonal antibody 2685 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody 7854 goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody, crossabsorbed 1706 goat anti-mouse IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1716 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1721 |
| Isotype control Mouse monocolonal IgG1 - Isotype Control |
| target relevance |
|---|
| GAPDH plays a crucial role in glycolysis, the metabolic pathway responsible for generating energy in cells. Due to its stable expression levels and essential role in cellular metabolism, GAPDH is commonly used as a loading control in various experimental techniques, such as Western blotting. As a loading control, GAPDH serves as a reference protein to normalize and ensure equal loading of protein samples across different lanes on a gel, compensating for variations in protein loading and gel transfer. Its relatively constant expression in most cells and tissues makes it an ideal standard for comparing protein levels, allowing researchers to accurately quantify and compare target protein expression in experimental samples. This antibody can be used as a loading control when run alongside proteins of interest with different and resolvable molecular weights and ideally in combination with antibodies of same host and when using a secondary antibody. Click for more on: loading controls and GAPDH |
| Protein names Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) (Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99.-) |
| Gene names GAPDH,GAPDH GAPD CDABP0047 OK/SW-cl.12 |
| Protein family Glyceraldehyde-3-phosphate dehydrogenase family |
| Mass 36053Da |
| Function Has both glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thereby playing a role in glycolysis and nuclear functions, respectively (PubMed:3170585, PubMed:11724794). Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis that catalyzes the first step of the pathway by converting D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate (PubMed:3170585, PubMed:11724794). Modulates the organization and assembly of the cytoskeleton (By similarity). Facilitates the CHP1-dependent microtubule and membrane associations through its ability to stimulate the binding of CHP1 to microtubules (By similarity). Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes (PubMed:23071094). Upon interferon-gamma treatment assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation (PubMed:23071094). Also plays a role in innate immunity by promoting TNF-induced NF-kappa-B activation and type I interferon production, via interaction with TRAF2 and TRAF3, respectively (PubMed:23332158, PubMed:27387501). Participates in nuclear events including transcription, RNA transport, DNA replication and apoptosis (By similarity). Nuclear functions are probably due to the nitrosylase activity that mediates cysteine S-nitrosylation of nuclear target proteins such as SIRT1, HDAC2 and PRKDC (By similarity). |
| Catalytic activity Reaction=D-glyceraldehyde 3-phosphate + NAD(+) + phosphate = (2R)-3-phospho-glyceroyl phosphate + H(+) + NADH; Xref=Rhea:RHEA:10300, ChEBI:CHEBI:15378, ChEBI:CHEBI:43474, ChEBI:CHEBI:57540, ChEBI:CHEBI:57604, ChEBI:CHEBI:57945, ChEBI:CHEBI:59776; EC=1.2.1.12; Evidence=; Reaction=L-cysteinyl-[protein] + S-nitroso-L-cysteinyl-[GAPDH] = L-cysteinyl-[GAPDH] + S-nitroso-L-cysteinyl-[protein]; Xref=Rhea:RHEA:66684, Rhea:RHEA-COMP:10131, Rhea:RHEA-COMP:17089, Rhea:RHEA-COMP:17090, Rhea:RHEA-COMP:17091, ChEBI:CHEBI:29950, ChEBI:CHEBI:149494; Evidence=; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66685; Evidence=; |
| Pathway Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 1/5. |
| Subellular location Cytoplasm, cytosol Nucleus Cytoplasm, perinuclear region Membrane Cytoplasm, cytoskeleton Note=Translocates to the nucleus following S-nitrosylation and interaction with SIAH1, which contains a nuclear localization signal (By similarity). Postnuclear and Perinuclear regions (PubMed:12829261). |
| Structure Homotetramer (PubMed:16239728, PubMed:16510976). Interacts with TPPP; the interaction is direct (By similarity). Interacts (when S-nitrosylated) with SIAH1; leading to nuclear translocation (By similarity). Interacts with RILPL1/GOSPEL, leading to prevent the interaction between GAPDH and SIAH1 and prevent nuclear translocation (By similarity). Interacts with CHP1; the interaction increases the binding of CHP1 with microtubules (By similarity). Associates with microtubules (By similarity). Interacts with EIF1AD, USP25, PRKCI and WARS1 (PubMed:11724794, PubMed:16501887, PubMed:15628863, PubMed:20644585). Interacts with phosphorylated RPL13A; inhibited by oxidatively-modified low-densitity lipoprotein (LDL(ox)) (PubMed:22771119). Component of the GAIT complex (PubMed:15479637). Interacts with FKBP6; leading to inhibit GAPDH catalytic activity (PubMed:19001379). Interacts with TRAF2, promoting TRAF2 ubiquitination (PubMed:23332158). Interacts with TRAF3, promoting TRAF3 ubiquitination (PubMed:27387501). |
| Post-translational modification S-nitrosylation of Cys-152 leads to interaction with SIAH1, followed by translocation to the nucleus (By similarity). S-nitrosylation of Cys-247 is induced by interferon-gamma and LDL(ox) implicating the iNOS-S100A8/9 transnitrosylase complex and seems to prevent interaction with phosphorylated RPL13A and to interfere with GAIT complex activity (PubMed:22771119, PubMed:25417112). ; ISGylated. ; Sulfhydration at Cys-152 increases catalytic activity. ; Oxidative stress can promote the formation of high molecular weight disulfide-linked GAPDH aggregates, through a process called nucleocytoplasmic coagulation. Such aggregates can be observed in vivo in the affected tissues of patients with Alzheimer disease or alcoholic liver cirrhosis, or in cell cultures during necrosis. Oxidation at Met-46 may play a pivotal role in the formation of these insoluble structures. This modification has been detected in vitro following treatment with free radical donor (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide. It has been proposed to destabilize nearby residues, increasing the likelihood of secondary oxidative damages, including oxidation of Tyr-45 and Met-105. This cascade of oxidations may augment GAPDH misfolding, leading to intermolecular disulfide cross-linking and aggregation. ; Succination of Cys-152 and Cys-247 by the Krebs cycle intermediate fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits glyceraldehyde-3-phosphate dehydrogenase activity. Fumarate concentration as well as succination of cysteine residues in GAPDH is significantly increased in muscle of diabetic mammals. It was proposed that the S-(2-succinyl)cysteine chemical modification may be a useful biomarker of mitochondrial and oxidative stress in diabetes and that succination of GAPDH and other thiol proteins by fumarate may contribute to the metabolic changes underlying the development of diabetes complications. ; (Microbial infection) Glycosylated by C.rodentium protein NleB, enteropathogenic E.coli protein NleB1 and S.typhimurium protein Ssek1: arginine GlcNAcylation prevents the interaction with TRAF2 and TRAF3 (PubMed:23332158, PubMed:27387501, PubMed:28522607). This leads to reduced ubiquitination of TRAF2 and TRAF3, and subsequent inhibition of NF-kappa-B signaling and type I interferon production, respectively (PubMed:23332158, PubMed:27387501). |
| Target Relevance information above includes information from UniProt accession : P04406 |
| The UniProt Consortium |
Data
 |
| Three loading control mAbs reacting against 10µg/lane of mouse brain tissue lysates. 50kDa band is Anti-β-Tubulin (#5007) at 1:2,000 dilution (0.5µg/mL); 42kDa band is Anti-β-Actin (#5132) at 1:1,000 dilution (1µg/mL); 37kDa band is Anti-GAPDH (#1937) at 1:5,000 dilution (0.2µg/mL). |
 |
| LEFT: 1:2,000 (0.5µg/mL) Ab dilution used in WB of 5µg/lane tissue lysates from human (1), mouse (2), rat (3), rabbit (4), chicken (5), and hamster (6). RIGHT: WB from BL-21 bacteria (1), Sf9 insect (2), and Saccharomyces cerevisiae (3). |
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.There are 539 publications in our database for this antibody or clone. Here are the latest 5, for more click below.
| pmid | title | authors | citation |
|---|---|---|---|
| 36833172 | Involvement of Mitochondrial Dysfunction in FOXG1 Syndrome | Bjerregaard VA, Levy AM, Batz MS, Salehi R, Hildonen M, Hammer TB, Møller RS, Desler C, Tümer Z. | Genes (Basel). 2023 Jan 17;14(2):246. doi: 10.3390/genes14020246. |
| 36831065 | Low-Molecular-Weight β-1,3-1,6-Glucan Derived from Aureobasidium pullulans Exhibits Anticancer Activity by Inducing Apoptosis in Colorectal Cancer Cells | Kim JH, Seo J, No H, Kuge T, Mori T, Kimoto H, Kim JK. | Biomedicines. 2023 Feb 11;11(2):529. doi: 10.3390/biomedicines11020529. |
| 36830676 | LRRK2 Kinase Inhibition Attenuates Astrocytic Activation in Response to Amyloid β(1-42) Fibrils | Filippini A, Salvi V, Dattilo V, Magri C, Castrezzati S, Veerhuis R, Bosisio D, Gennarelli M, Russo I. | Biomolecules. 2023 Feb 6;13(2):307. doi: 10.3390/biom13020307. |
| 36818283 | Role of human HSPE1 for OPA1 processing independent of HSPD1 | Yeung N, Murata D, Iijima M, Sesaki H. | iScience. 2023 Jan 26;26(2):106067. doi: 10.1016/j.isci.2023.106067. eCollection 2023 Feb 17. |
| 36685538 | Duck TRIM29 negatively regulates type I IFN production by targeting MAVS | Li W, Song Y, Du Y, Huang Z, Zhang M, Chen Z, He Z, Ding Y, Zhang J, Zhao L, Sun H, Jiao P. | Front Immunol. 2023 Jan 6;13:1016214. doi: 10.3389/fimmu.2022.1016214. eCollection 2022. |
Protocols
| relevant to this product |
|---|
| Western blot ICC |
Documents
| # | |||
|---|---|---|---|
| No results found | |||
7 reviews for mouse anti-GAPDH monoclonal antibody (GA1R) 1937
Only logged in customers who have purchased this product may leave a review.
verified user –
verified user –
verified user –
verified user –
verified user –
verified user –
verified user –